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Towards an evidence-informed value scale for surgical and 
radiation oncology: a multi-stakeholder perspective
Yolande Lievens, Riccardo Audisio, Ian Banks, Laurence Collette, Cai Grau, Kathy Oliver, Richard Price, Ajay Aggarwal
Surgery and radiotherapy, two locoregional cancer treatments, are essential to help improve cancer outcomes, control, 
and palliation. The continued evolution in treatment processes, techniques, and technologies—often at substantially 
increased costs—demands for direction on outcomes that are most valued by patients, and the evidence that is 
required before clinical adoption of these practices. Three recently introduced frameworks—the European Society for 
Medical Oncology Magnitude of Clinical Benefit Scale, the American Society of Clinical Oncology Value Framework, 
and the National Comprehensive Cancer Network Blocks—which all help define the value of oncology treatments, 
were appraised with a focus on their methods and definition of patient benefit. In this Review, we investigate the 
applicability of these frameworks to surgical and radiotherapy innovations. Findings show that these frameworks are 
not immediately transferable to locoregional cancer treatments. Moreover, the lack of emphasis on patient perspective 
and the reliance on traditional, trial-based endpoints such as survival, disease-free survival, and safety, calls for a new 
framework that includes real-world evidence with focus on the whole spectrum of patient-centred endpoints. Such an 
evidence-informed value scale would safeguard against the proliferation of low-value innovation while simultaneously 
increasing access to treatments that show significant improvements in the outcomes of cancer care.
Introduction
Across Europe, cancer care expenditures continue to 
rise exponentially, driven by the demographic transition 
of a growing ageing population, numerous therapeutic 
advances, and expanding choice and consumerism in 
health care.1,2 In any health-care system it is essential that 
patients have access to therapies most likely to deliver 
tangible and sustainable improvements in outcome, 
whether it is survival, quality of life, reduced toxicity, the 
ability to return to work, or the ability to maintain a 
patient’s prediagnosis level of activity. Additionally, 
health-care investment should obtain the highest level of 
health for the entire society. Yet, the increasing costs of 
cancer care do not de facto translate into overall 
improvements in health outcomes, partly because of 
substantial expenditures of new treatments that are of 
uncertain benefit.3–7
Harvard Business School professor, Micheal Porter, 
proposed8 that to achieve value-based health care, the 
focus should be on increasing value for patients, in other 
words, increasing health outcomes that matter to 
patients, per dollar spent. However, understanding the 
true benefits of new treatment modalities remains a 
challenge because benefits are measured from a clinical 
trial perspective (eg, survival and progression-free 
survival) and there is little understanding of how a 
patient values these outcomes and how their disease and 
background influence the perceived value of these 
outcomes. In this context, the European Society for 
Medical Oncology (ESMO) and the American Society of 
Clinical Oncology (ASCO) developed evidence-informed 
value frameworks that provide guidance on the likely 
benefits of newly approved cancer medicines.9–12 Similarly, 
the National Comprehensive Cancer Network (NCCN) in 
the USA developed the NCCN Evidence Blocks, a tool 
that visually represents five key measures on the value of 
cancer treatments delivered in accordance with NCCN 
guidelines.13 These frameworks mainly focus on 
categorising clinically meaningful benefits of new 
treatments to help inform decision making. Conversely, 
organisations such as the International Consortium for 
Health Outcomes Measurement (ICHOM) define how to 
capture, in a standardised way, the diverse range of 
benefits that long-established or new interventions might 
offer to patients throughout their entire disease history.14
Radiotherapy and surgery are locoregional cancer 
treatments that are key to multidisciplinary cancer care, 
whether they are used to improve survival, for tumour 
control, or palliation.15–18 Whilst half of all patients with 
cancer have an indication for radiotherapy, up to 80% of 
patients will need one or more surgical intervention.15,16,18,19 
Inspite of this, these interventions have largely remained 
outside the scope of value frameworks because the 
evolution of these innovations and their financing 
mechanisms, and thus market access, are different. Before 
market introduction, new technologies only need to show 
safety20 and although health technology assessments 
(HTA) become a prerequisite for reimbursement in some 
countries, these HTA processes still lag behind those 
required for systemic therapies.21–26 Neither the concept nor 
the methods on how to address HTA for technologies has 
been accepted at a European level.27,28 Furthermore, 
although there are excellent examples of randomised 
controlled trials (RCTs) in surgery and radiotherapy, a 
dependence on lower levels of evidence before clinical 
adoption persists, the reasons for which are 
multifaceted.20,29–37 Hence, a rapid uptake of new surgical 
and radiotherapy technologies has been observed, even 
without robust comparative effectiveness data that 
supports one modality over another.38 This uptake might 
be further stimulated by the fact that new treatments 
(eg, technologies and medicines) are often presented as 
breakthroughs or game changers in the absence of clear 
evidence.
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A position paper by the European CanCer Organisation 
(ECCO)39 showed the need for a public policy debate on 
access to innovation beyond the current policy focus on 
new pharmaceutical treatments. It questioned how to 
expand access to improved diagnostic procedures and 
more effective forms of surgery and radiotherapy whilst 
ensuring multidisciplinary health-care remains 
sustainable for all patients with cancer across Europe. 
The paper also calls for more consistent measurement of 
the value of any innovation that is rooted in a common 
understanding of its clinical effectiveness and added 
value to patients.39
The current project was performed by a multi-
stakeholder taskforce of medical, policy, and patient 
advocacy experts representing ECCO, the European 
Society for Radiotherapy and Oncology (ESTRO), the 
European Society of Surgical Oncology, and the European 
Organisation for Research and Treatment of Cancer. 
Although formal endorsement by each separate 
organisation was not carried out, the project took place 
under the oversight of the ECCO Oncopolicy Committee, 
which was acting on behalf of ECCO’s 28 member 
organisations regarding policy projects and documents. 
In this Review, three existing cancer value frameworks 
are evaluated and RCTs in radiation and surgical 
oncology are tested with two of these tools. Subsequently, 
the challenges in defining a robust and transparent 
mechanism that can better, and more consistently, 
appraise the value of new loco-regional cancer treatments, 
are addressed.
Value frameworks in oncology: the current status
The increasing narrative around value-based health care 
has led to several initiatives seeking to assist the 
development of a more consistent definition of the 
clinically meaningful benefit and value of treatments. Our 
analysis focused on three value frameworks specifically 
developed for the context of oncology: the ESMO 
Magnitude of Clinical Benefit Scale (ESMO-MCBS), the 
ASCO Value Framework (ASCO-VF), and the NCCN 
Blocks (NCCN-B).9–13 These are the main tools that have 
been used in the medical research literature for considering 
the value of oncology interventions, specifically for 
drug treatments.40,41 Additionally, information on the 
development of these scales has been published to enable 
detailed appraisal of their methods, unlike information on 
the development of other scales, such as the Memorial 
Sloan Kettering Cancer Center’s Drug Abacus, of which 
the methodological description is not available in 
publications. Moreover, these three value scales that this 
Review focuses on differ methodologically from the 
approach used by HTA bodies such as the UK National 
Institute of Health and Care Excellence framework and the 
American Institute for Clinical and Economic Review 
framework. Value scales appraise both the strength of 
clinical evidence and the expected added benefit for the 
patient of a particular intervention, whereas HTA tools 
tend to focus on whether an intervention meets a 
predefined threshold for cost per outcome.
The general aspects of the three value scales are shown 
in table 1.9–13 ESMO-MCBS and ASCO-VF were 
specifically developed to appraise the value of oncology 
medicines in the curative and palliative setting, whereas 
NCCN-B does not specify treatment modalities nor 
intents. ASCO-VF and NCCN-B cover haematological 
malignancies and solid tumours, whereas ESMO-MCBS 
only focuses on solid tumours. Clinicians have been the 
primary drivers in the development of these three value 
tools. Patients and the public, on the other hand, were 
not consulted in the initial development of these tools, 
although both were the intended end users for ASCO-VF, 
whilst only patients were the intended end users for 
NCCN-B. ASCO-VF and NCCN-B also aim to provide 
professional peer support for clinicians, which is in 
contrast with ESMO-MCBS, in which the primary aim is 
to inform payers and policy makers of the value of new 
anticancer drugs to support market access. However, the 
nature of these frameworks is evolving through their 
application, and the need for patient input is increasingly 
being recognised.42 For example, ESMO-MCBS has 
ESMO-MCBS ASCO-VF NCCN-B
Cancer types
Solid tumours Included Included Included
Haematological 
malignancies
Not included Included Included
Treatment intent
Curative/adjuvant Included Included Not stated
Palliative Included Included Not stated
Treatment modalities
Systemic anticancer 
therapies
Included Included Included
Radiotherapy Not included Not included Not stated
Surgery Not included Not included Not stated
Development team
Physicians Included Included Included
Nurses Not included Not included Not included
Epidemiologists Not included Not included Not included
Statisticians Included Not stated Not included
Patients Not included Not included Not included
Patient advocates Not included Not included Not included
Public Not included Not included Not included
Intended users and stakeholders
Patients Not included Included Included
Providers Not included Included Included
Payers Included Not included Not included
Policy makers Included Not included Not included
Public Not included Included Not included
ESMO-MCBS=European Society for Medical Oncology Magnitude of Clinical 
Benefit Scale. ASCO-VF=American Society of Clinical Oncology Value Framework. 
NCCN-B=National Comprehensive Cancer Network Blocks.
Table 1: General aspects of value frameworks
For the UK National Institute of 
Health and Care Excellence see 
https://www.nice.org.uk/
For the American Institute for 
Clinical and Economic Review 
see https://icer-review.org/
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started consultations with patients and plans the 
inclusion of patient input in the next iteration of its tool.10 
Similarly, reflecting the feedback from patients who 
emphasised that even mild side-effects can have a major 
effect on quality of life, the new version of ASCO-VF now 
considers all side-effects in its value framework, instead 
of only the most severe.12
Table 2 shows the endpoints of the different value tools. 
ASCO-VF and NCCN-B take into account key criteria that 
define value-based health care: outcomes and costs.11–13 
Conversely, ESMO-MCBS only focuses on outcome, 
because it recognises this as the first step to determine 
value in cancer care.9,10
Costs are addressed differently by ASCO-VF and 
NCCN-B. In the ASCO-VF tool, the direct costs of the 
treatment are defined by the drug acquisition cost 
(anticancer and supportive care drugs) and the related 
patient co-payments.11 ASCO-VF acknowledges that other 
costs, such as hospital, physician visits, or costs related to 
work missed by the patient or caregivers, could be 
substantial, but they are not included in the analysis 
because they are not readily available nor easily 
quantifiable.12 In the NCCN-B tool, the financial issue is 
approached more broadly as affordability, and is rated 
using the experts’ knowledge of the overall cost of the 
regimen, including drug cost, supportive care, infusions, 
toxicity monitoring and management. This estimation of 
affordability by the NCCN-B, defined on a scale ranging 
from very inexpensive to very expensive, implies a health 
system perspective: it uses the costs for the health-care 
system and questions the interventions’ affordability for 
the society who pays for it.13
A similar broader approach is taken by the NCCN-B 
scale regarding outcome: although it is mainly based on 
evidence derived from clinical trials, the knowledge is 
complemented by real-life evidence obtained through 
expert opinion, and therefore includes effectiveness 
data.13 Conversely, the ASCO-VF and the ESMO-MCBS 
scales only focus on efficacy obtained from clinical 
trials.9–12 In general, NCCN-B defines the endpoints 
considered in its tools less explicitly but defines outcome 
in terms of long-term survival, curative potential, or 
disease control.13
Overall, progression-free and disease-free survival are 
covered by all three value tools, either explicitly 
(ESMO-MCBS and ASCO-VF) or implicitly (NCCN-B). 
Treatment-free interval is addressed by ASCO-VF and 
NCCN-B, with NCCN-B also evaluating local disease 
control. Although toxicity is included in all three tools, 
palliation of symptoms is only covered in ASCO-VF and 
NCCN-B, whereas ESMO-MCBS was the only tool that 
initially incorporated quality of life in its algorithms. 
However, the revised version of ASCO-VF introduced 
quality of life in the evaluation of treatments for advanced 
disease, providing bonus points to the intervention 
evaluated through the ASCO-VF scale. It is also worth 
acknowledging that toxicity is typically scored at early 
onset during or shortly after treatment. But the revised 
version of ASCO-VF subtracts points in case symptomatic 
treatment-related toxicities do not resolve within 1 year 
post treatment. Similarly, in NCCN-B, a block is deduced 
for safety when substantial chronic or long-term toxic 
effects occur.9–13
As mentioned, NCCN-B derives its evaluation on the 
entire spectrum of available evidence, from meta-
analyses to expert opinion.13 ESMO-MCBS and ASCO-VF 
mainly define the ranking of clinical benefit on the basis 
of evidence from RCTs,9,11 although ESMO-MCBS has 
more recently broadened this defenition to include 
single-arm phase 2 trials.10 Table 3 provides an overview 
of the evidence included in the various tools.
Both ESMO-MCBS and ASCO-VF used a statistical 
approach to weigh the defined endpoints and integrate 
ESMO-MCBS ASCO-VF NCCN-B
Key criteria VBHC
Outcome Efficacy Efficacy Efficacy and 
effectiveness
Cost Not stated Direct cost Affordability
Clinical endpoints
Overall survival Included Included Not stated
Progression-free survival Included Included Not stated
Disease-free survival Included Included Not stated
Treatment-free interval Not included Included Not stated
Cause-specific survival Not included Not included Not included
Response rate Included Included Not included
Treatment-related mortality Not included Included Not included
Locoregional control Not included Not included Not stated
Organ preservation Not included Not included Not included
Reintervention rate Not included Not included Not included
Quality of life Included Included Not included
Toxicity and safety Included Included Included
Palliation of symptoms Not included Included Included
ESMO-MCBS=European Society for Medical Oncology Magnitude of Clinical Benefit Scale. ASCO-VF=American Society 
of Clinical Oncology Value Framework. NCCN-B=National Comprehensive Cancer Network Blocks. VBHC=value-based 
health care.
Table 2: Endpoints used in value frameworks
ESMO-MCBS ASCO-VF NCCN-B
Meta-analyses Not included Not included Included
Phase 3 trials Included Included Included
Phase 2 trials Included Not included Included
Cohort studies Not included Not included Not stated
Case-control studies Not included Not included Not stated
Case series Not included Not included Not stated
Expert opinion Not included Not included Included
ESMO-MCBS=European Society for Medical Oncology Magnitude of Clinical 
Benefit Scale. ASCO-VF=American Society of Clinical Oncology Value Framework. 
NCCN-B=National Comprehensive Cancer Network Blocks.
Table 3: Level of evidence addressed in value frameworks
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them into a formal value metric, ranking the magnitude 
of clinically meaningful benefit and the net health benefit. 
As such, these tools enable comparative analysis of the 
value of different anticancer drugs.9–12 NCCN-B shows the 
results of its appraisal visually by using Value Blocks.13
Defining relevant endpoints from a 
multi-stakeholder perspective
The available value tools in oncology mainly target 
systemic anticancer treatments rather than locoregional 
cancer interventions, such as radiotherapy and 
surgery. Additionally, as shown in table 2, the existing 
frameworks are essentially built around four outcomes to 
measure benefit to the patients, reflecting market 
authorisation requirements: overall survival, progression-
free survival, safety, and health-related quality of life. 
However, when it comes to gauging the benefit of 
locoregional therapies it is likely that the frameworks 
should be more nuanced than those used to assess drugs, 
reflecting the specificities of locoregional treatments. 
Beyond the mere issue of survival or prolongation of life, 
endpoints such as symptom control, organ preservation, 
peri-operative and post-operative complications, or 
functional outcomes are also of great importance. Such 
endpoints are absent from the current value framework 
tools evaluating clinically meaningful benefit.
Additionally, not all of these endpoints will be relevant 
to every surgical or radiotherapeutic innovation, but 
Setting Comparators Objective Trial design Primary endpoint Secondary endpoints
PARSPORT, Nutting 
and colleagues 34
Head and neck 
cancer, pharyngeal 
SSC, primary 
radiotherapy
Conventional 
radiotherapy vs 
intensity-modulated 
radiotherapy
Assess whether 
parotid- sparing 
intensity-modulated 
radiotherapy reduces 
the incidence of severe 
xerostomia
Phase 3 Percentage of patients 
with grade ≥2 
xerostomia 1 year after 
radiotherapy
Survival: OS and LR-PFS; toxicity: acute toxicity 
and other late side-effects; QoL and PROM: 
xerostomia in xerostomia-modified 
questionnaire; other: percentage of patients with 
any measurable salivary flow after radiotherapy
AMAROS, Donker 
and colleagues33
Breast cancer, 
positive sentinel 
node, adjuvant 
regional treatment
Axillary lymph node 
dissection vs axillary 
radiotherapy
Assess whether axillary 
radiotherapy provides 
comparable regional 
control with fewer 
side-effects
Phase 3, 
non-inferiority
5-year axillary 
recurrence
Survival: OS, DFS, and axillary RFS; toxicity: late 
toxicity (shoulder mobility and lymphoedema); 
QoL/PROM: symptom scores EORTC-QLQ-C30 
and QLQ-BR23
APBI GEC-ESTRO, 
Strnad and 
colleagues31
Breast cancer, low 
risk after 
breast-conserving 
surgery, primary 
radiotherapy
Brachytherapy APBI vs 
WBI
Assess whether APBI 
using multicatheter 
brachytherapy is 
non-inferior to WBI 
with respect to local 
control
Phase 3, 
non-inferiority
Ipsilateral local 
recurrence
Survival and clinical: OS, DFS, and cumulative 
incidence of regional and distant recurrence; 
toxicity: acute and late toxicity; QoL and PROM: 
QoL non-otherwise specified; other: cosmesis and 
rate of contralateral breast cancer
LRT metastatic 
breast cancer, 
Badwe and 
colleagues36
Metastatic breast 
cancer, surgical 
treatment of 
primary disease
Surgery vs no surgery 
to primary tumour
Assess whether LR 
surgery improves 
outcome in metastatic 
breast cancer
Phase 3 OS Survival: LR-RFS, distant PFS; QoL/PROM: QoL 
EORTC QLQ C-30 and BR23
CHIPP, Dearnaley 
and colleagues30
Localised prostate 
cancer, primary 
radiotherapy
74 Gy/37 fractions vs 
60 Gy/20 fractions or 
57 Gy/19 fractions
Efficacy and 
side-effects of 
conventional and 
hypofractionated 
radiotherapy
Phase 3, 
non-inferiority
Time to biochemical or 
clinical failure
Survival and clinical: OS, DFS, development of 
metastases; toxicity: acute bowel and bladder 
toxicity: peak and at 18 weeks, late grade ≥2 
toxicity at 2 years and 5 years, time to 
development of grade 1–3 toxicity; QoL/PROM: 
symptom scores in UCLA-PCI and EPIC-50; other: 
recommencement of hormonal treatment for 
disease recurrence
ROLARR, Jayne and 
colleagues32
Rectal cancer, 
primary 
laparoscopic surgery
Robotic-assisted vs 
conventional 
laparoscopic surgery
Assess risk of 
conversion to open 
laparotomy
Randomised, 
unblinded, 
parallel-group trial
Rate of conversion to 
open surgery
Survival and clinical: 30 days mortality and local 
recurrence; complications: intraoperative 
complications; QoL: 36-Item Short Form Survey 
and 20-item Multidimensional Fatigue Inventory; 
PROMs: bladder and sexual function in 
International Prostate Symptom Score, 
International Index of Symptom Score, 
International Index of Erectile Function, and 
Female Sexual Function Index; and other: margin 
status, quality of the plane of surgery
STAMPEDE, Parker 
and colleagues35
Metastatic prostate 
cancer, radiotherapy 
of primary tumour
Standard of care for 
metastatic prostate 
cancer, with or 
without radiotherapy
Assess survival benefit 
of adding radiotherapy 
to primary tumour
Phase 3 OS (failure-free 
survival for the interim 
analysis)
Survival: PFS, M-PFS, and prostate cancer-specific 
survival; toxicity: symptomatic local events
APBI=accelerated partial breast irradiation. DFS=disease-free survival. EORTC=European Organisation for Research and Treatment of Cancer. LR-PFS=local-relapse progression-free survival. LR=local relapse. 
LRT=locoregional therapy. M-PFS=metastatic progression-free survival. OS=overall survival. PFS=progression-free survival. PROM=patient-reported outcome measurement. RFS=relapse-free survival. 
SCC=squamous cell carcinoma. QoL=quality of life. WBI=whole-breast irradiation.
Table 4: Analysis of trial design and endpoints used in seven randomised controlled trials in radiation or surgical oncology
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instead depend on the cancer type, the treatment intent, 
and the nature of the intervention evaluated, whether it 
is new technologies, treatment techniques, or treatment 
schedules, which could be in combination or not with 
systemic drugs.43 Table 4 describes the endpoints used in 
seven RCTs that explore the role of surgery and 
radiotherapy in prostate, colorectal, head and neck, and 
breast cancers.30–36 Although traditional endpoints are 
relevant in these studies, the primary focus is often 
centred around improving local control and long-term 
function,30,31,33 or reducing operative complications and 
acute and late toxicity,32,34 which are neglected—or not 
given sufficient weightings—in the scoring system of 
current value frameworks.
For example, local control that allows organ sparing 
and function preservation could have a substantially 
positive effect on the wellbeing of the patient. Examples 
include those where the glottis, the breast, or a limb can 
be spared or cosmesis or function improved because of a 
judicious choice between radiotherapy and surgery, or a 
combination of radiotherapy with less mutilating surgery. 
The AMAROS trial is one example of a trial that uses a 
combination of radiotherapy with less mutilation surgery 
in the setting of breast cancer.33 Local control, or at least 
reduction of local tumour burden, is also crucial in 
relieving symptoms.44
For toxicity, it is important to emphasise the distinction 
between acute toxic effects that could be unavoidable and 
Improvement of OS Improvement of 
DFS
Reduced treatment toxicity or improved 
QoL
Reduced treatment 
cost
Magnitude of Clinical 
Benefit Grade
PARSPORT, Nutting 
and colleagues34
2-year OS was 76% conventional 
radiotherapy vs 78% IMRT; 2-year OS 
HR was 0·68 (95% CI 0·34–1·37)
Not reported Proportion of patients with grade ≥2 
xerostomia at 1 year was 74% with 
conventional radiotherapy vs 38% with IMRT 
(p=0·0027); grade ≥2 acute fatigue was 41% 
with conventional radiotherapy vs 74% with 
IMRT, p=0·0015; significant benefits in 
recovery of saliva secretion with IMRT; 
clinically significant improvements in dry 
mouth-specific and global QoL with IMRT
Not reported Form 1: grade B; reduced 
toxicity (xerostomia) and 
improved QoL
AMAROS, Donker and 
colleagues33
5-year OS was 93·3% LND vs 92·5% 
radiotherapy; 5-year OS HR was 1·17 
(95% CI 0·85–1·62)
5-year DFS was 
86·9% LND vs 82·7% 
radiotherapy; 5-year 
DFS HR was 1·18 
(95% CI 0·93–1·51)
Clinical lymphoedema at 5 years was 23% vs 
11% (p<0·0001); 10% arm circumference 
increase at 5 years was 13% vs 5% (p=0·0009); 
shoulder mobility at 5 years was no 
difference; no significant differences in QoL
Not reported Form 1: grade B reduced 
toxicity
APBI GEC-ESTRO, 
Strnad and colleagues31
5-year OS was 95·55% WBI vs 97·27% 
APBI (p=0·11) and HR was not reported
5-year DFS was 
94·45% WBI vs 
95·03% APBI 
(p=0·79); HR was not 
reported
5-year grade 2–3 late skin side-effects was 
5·66% with WBI vs 3·23% with APBI 
(p=0·0807); 5-year grade 3 fibrosis was 0·23% 
with WBI vs 0% with APBI (p=0·4561); 5-year 
grade 3 breast pain was 3·17% with WBI vs 
1·14% with APBI (p=0·0389)
Not reported Form 1: grade B reduced 
breast pain
LRT metastatic breast 
cancer, Badwe and 
colleagues36
2-year OS was 41·9% LRT vs 43·0% no 
LRT; 2-year OS HR was 1·04 (95% CI 
0·81–1·34)
Not reported Apart from one grade 3 adverse event 
(wound infection) in the LRT group, no other 
adverse events were reported; QoL was not 
reported
Not reported Form 2a: grade 1 no OS 
benefit observed (ie, no 
benefit from surgical 
intervention)
CHIPP,* Dearnaley and 
colleagues30
5-year OS HR was 0·78 (95% CI 
0·57–1·05)
5-year DFS HR was 
0·83 (95% CI 
0·68–1·01)
Worse acute bowel toxicity was 25% with 74 
Gy vs 38% with 60 Gy; no difference in acute 
bladder toxicity; no difference in late toxicity 
at 5 years; and no difference in PROMs at 
5 years
Not reported Form 1 was not gradable; but 
grade B if expected lower cost 
of hypo-fractionation would 
be factored in
ROLARR, Jayne and 
colleague32
Not reported Not reported No difference in intra-operative 
complications; no difference in 30-day 
complications; no difference in complications 
at 6 months; no difference in bladder or 
sexual function at 6 months
Higher cost of 
robotic-assisted 
laparoscopic surgery
Form 1 was not gradable 
because the study did not 
show superiority of the 
investigational approach
STAMPEDE, Parker and 
colleagues35
All cases*: 3-year OS was 62% with no 
radiotherapy vs 65% with radiotherapy; 
HR 0·92 (95% CI 0·80–1·06); cases with 
low metastatic burden*: 3-year OS was 
73% with no radiotherapy vs 81% with 
radiotherapy; HR:0·68 (95% CI 
0·52–0·90)
Not reported Some radiotherapy toxicity, but no difference 
in symptomatic local event-free survival
Not reported Form 2a was not gradable; 
total population* had no OS 
gain; cases with low 
metastatic burden*: HR was 
<0·70 but median OS not 
reached
All trials are evaluated with the European Society for Medical Oncology Magnitude of Clinical Benefit Scale v1.1 form 1, except for the trial of Badwe and colleagues,36 for which form 2a for OS with the standard 
treatment >12 and <24 months was used, and of Parker and colleagues, for which form 2a for median OS with the standard treatment >24 months was used. Improvement in pathological complete response 
was not included in the table. APBI=accelerated partial breast irradiation. Conv=conventional radiotherapy. DFS=disease-free survival. HR=hazard ratio. IMRT=intensity-modulated radiotherapy. LND=lymph 
node dissection. LRT=locoregional therapy. OS=overall survival. QoL=quality of life. WBI=whole-breast irradiation. *Comparison only for 74 Gy versus 60 Gy.
Table 5: Analysis of trials according to ESMO-MCBS
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acceptable in case of treatments with curative intent and 
late toxic effects, occurring months to years after 
treatment especially for radiotherapy, which should be 
minimised as much as possible. Innovations in 
radiotherapy often focus on decreased long-term toxicity 
and the consequential effect on quality of life.20,31,33,34 
Additionally, better techniques could allow the reduction 
of the intensity, duration, and financial cost of toxicity of 
a treatment compared with existing standards without 
compromising functional or oncological outcomes.30
Tables 5 and 6 also show the evaluation of the selected 
trials using the ESMO-MCBS tool (version 1.1: form 1 for 
curative intent and form 2a for the metastatic setting, 
which accounts for survival with standard treatment) and 
ASCO-VF (both for the adjuvant setting and advanced 
disease).10,12 Appraisal with NCCN-B was not performed 
because NCCN-B is essentially a tool for evidence 
synthesis for a particular intervention with no real 
assessment of comparators within trials.13 Although all 
evaluated trials have informed and affected practice29—or 
are expected to do so—they either resulted in low clinical 
benefit grades because of their sole effect on toxicity and 
quality of life,31,33,34 or turned out difficult to appraise with 
the current value frameworks as the trial endpoints used 
were not reflected in the tools. This situation shows that 
the selection of endpoints is crucial when considering 
the value of new locoregional cancer treatments, as well 
as differentiating between surrogates and hard endpoints 
that have influenced the weightings applied in the scales 
discussed.
Several questions remain following this evaluation. Do 
we have the adequate tools to define the relative benefits 
and value of different treatment approaches for the same 
indication? Are the available tools ready to capture 
additional aspects of care that matter to patients, such as 
shorter and less intensive treatment schedules and the 
CB; OS; DFS (PFS)*; response rate Toxicity; grading of acute toxicity 
and unresolved treatment-related 
toxic effects after 1 year
Bonus points; tail of the curve, 
palliation, QoL, and treatment-free 
interval*
Net health benefit
PARSPORT, Nutting and 
colleagues34
2-year OS HR was 0·68 (95% CI 
0·34–1·37); median OS was not reported; 
DFS HR was not reported; and unresolved 
symptomatic treatment-related toxic 
effects lower after IMRT
Acute side-effects 0·5 point higher 
in IMRT
OS curves not reported Adjuvant form not gradable; no 
difference in survival acute toxicity 
similar and decrease in late toxicity 
cannot be rewarded
AMAROS, Donker and 
colleagues33
5-year OS HR was 1·17 (95% CI 
0·85–1·62); 5-year DFS HR was 
1·18 (95% CI 0·93–1·51); unresolved 
symptomatic treatment-related toxic 
effects lower after RT
Acute toxicity not reported Tail of the curve bonus not applicable Adjuvant form not gradable; 
no difference in survival and decrease in 
late toxicity cannot be rewarded
APBI/GEC-ESTRO, Strnad 
and colleagues31
HR OS was not reported; no difference in 
OS; median OS not reported; HR DFS not 
reported, no difference in DFS unresolved 
symptomatic treatment-related toxic 
effect slower after APBI
Acute toxicity not reported; no 
difference
Tail of the curve bonus not applicable Adjuvant form not gradable; no 
difference in survival and decrease in 
late toxicity cannot be rewarded
LRT metastatic, breast 
cancer Badwe and 
colleagues36
2-year OS HR was 1·04 (95% CI 
0·81–1·34); no difference in unresolved 
symptomatic treatment-related toxic 
effects
Acute toxicity not reported Palliation bonus not applicable; 
QoL bonus not applicable; and 
treatment-free interval bonus not 
applicable
Advanced form not gradable; 
no difference in survival; and no 
difference in other outcomes
CHIPP †,Dearnaley and 
colleagues30
5-year OS HR was 0·78 (95% CI 
0·57–1·05); 5-year DFS HR was 0·83 
(95% CI 0·68–1·01); and no difference in 
unresolved symptomatic treatment-
related toxic effects at year 5
Acute toxicity reported for grade ≥2; 
and no separate evaluation possible 
for grades 1–2 and grades 3–4
Tail of the curve bonus not applicable Adjuvant form not gradable; 
no difference in survival; and no 
difference in other outcomes advantage 
shorter fractionation schedule cannot 
be rewarded
ROLARR, Jayne and 
colleagues32
OS HR not reported; median not 
reported; and DFS HR not reported
Acute toxicity not reported; no 
difference in complications at 
30 days and 6 months
Tail of the curve bonus not applicable Adjuvant form not gradable; and no 
difference in survival, no difference in 
other outcomes
STAMPEDE, Parker and 
colleagues35
For total population*: 5-year OS HR was 
0·92 (95% CI 0·80–1·06); slightly higher 
grade 3–4 late toxicity after radiotherapy 
4% vs no radiotherapy 1%; for low 
metastatic subgroup*: 5-year OS HR was 
0·68 (95% CI 0·52–0·90)
Acute radiotherapy-related toxicity 
reported lower for weekly than for 
daily schedule; symptomatic local 
events similar
Palliation bonus not applicable; 
QoL bonus not applicable; 
treatment-free interval bonus not 
applicable, time to any therapy similar; 
tail of the curve bonus applicable; no 
palliation, QoL, or TFI applicable; and 
bonus was 20 points
The advanced form was not gradable for 
the total population; for the low 
metastatic subgroup, scoring with the 
advanced form resulted in a CB of 32 
and 0 toxicity, which allowed adding 20 
bonus points, resulting in a net health 
benefit of 52
All trials are evaluated with the American Society of Clinical Oncology Value Framework (ASCO-VF) updated form for adjuvant therapy, except for the trials of Badwe and colleagues36 and Parker and colleagues,35 
for which the advanced disease form was used. Improvement in pathological complete response  was not included in the table. Only net health benefit was evaluated; no evaluation of treatment costs was 
included as ASCO-VF focuses on drug acquisition costs only. CB=clinical benefit. OS=overall survival. DFS=disease-free survival. PFS=progression-free survival. TFI=treatment-free interval. HR=hazard ratio. 
QoL=quality of life. APBI=accelerated partial breast irradiation. IMRT=intensity-modulated radiotherapy. LRT=locoregional therapy. RT=radiotherapy.*Applies to evaluation in the advanced form. †Comparison 
only for 74 Gy versus 60 Gy.
Table 6: Analysis of trials according to ASCO-VF
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ability to return to normality or to return to work? Patient 
advocates show that framing value is complex and 
ultimately not compatible with one single homogeneous 
set of patient values.42,45 It is influenced by external factors 
such as the health-care, social, religious, and cultural 
environments, and patient-specific factors such as age, 
gender, education, and personal finances. To capture this 
rich spectrum of values, frameworks should consider not 
only the clinical effects of a treatment but also its practical 
burden that impacts patients’ wellbeing, and they should 
attempt to incorporate the broader range of outcomes 
that patients could regard as most relevant.42
The ICHOM has gone beyond traditional endpoints of 
survival and disease control. It does not appraise the 
quality of evidence or degree of benefit, but instead 
recommends a range of outcome measures and 
instruments that they consider best captures value from 
the patient perspective. Standard sets of patient-centred 
outcome measurements have been developed for various 
medical conditions,14 including breast, lung, colorectal 
and prostate cancers.46–50 Table 7 shows the main 
differences and overarching aims and methods between 
the ICHOM and the other three scales described. The 
ICHOM includes outcomes that pertain to the entire 
disease history of a patient, such as long-term treatment 
complications, the degree of health that can be recovered, 
and the quality of death. ICHOM aims to standardise 
patient outcomes routinely collected in clinical practice 
and trials to reflect the diverse range of benefits that new 
and existing interventions could offer to patients, and 
to allow benchmarking as part of quality assurance 
processes following clinical adoption. The importance of 
a multi-stakeholder approach to identify endpoints for 
new interventions in the context of trials and for 
processes of care has stimulated several tumour-specific 
initiatives that develop core outcome sets in cancer 
surgery (eg, in oesophageal and colorectal surgery).51,52
How to appraise the outcome of locoregional 
cancer treatments: a question of evidence
The development of a value framework for locoregional 
cancer treatments poses various challenges, in particular 
how to overcome the issue of the different levels of 
evidence available regarding patient benefit when 
compared with systemic therapies. Available value 
frameworks are mainly based on evidence from RCTs 
(table 3), which are less common when assessing new 
technologies in surgical or radiation oncology. An 
evaluation of global radiotherapy research between 2001 
and 2015 showed that only 5% of publications were 
devoted to clinical trials.43 In their absence, small-scale 
observational studies and more latterly modelling studies 
have been used as the evidence standard for many new 
technologies before clinical adoption. In circumstances 
where the minimum requirement by regulators is to 
show safety, the use of lower evidence levels could bear 
the risk of integrating low-value technologies that are 
both expensive and unlikely to deliver tangible 
improvements in the experience and outcome of patients.
One observed barrier is that funding for trials of non-
pharmaceutical technologies lags behind that for trials of 
pharmaceuticals; for example, only 5% of cancer funding 
goes into surgical trials.37 However, assessing innovation 
in surgery and radiotherapy is also inherently more 
complex than assessing new cancer drugs, and RCTs that 
include a surgical or radiotherapeutic technique might 
not be feasible or appropriate in every indication.53,54
In radiotherapy, innovations can include everything 
from the assessment of a new treatment indication 
and new treatment schemes (eg, different doses and 
fractionation schedules and novel combinations with 
systemic drugs), to new techniques for targeting and 
localising the tumour (eg, imaging before and during 
radiotherapy) or treatment delivery (eg, intensity-
modulated radiotherapy, stereotactic body radiotherapy). 
They also include irrradiation with different biological 
entities (eg, protons) as well as new technologies (eg, 
magnetic resonance-based radiotherapy) and methods of 
immobilisation (eg, masks). In addition to the range of 
relevant endpoints for surgery and radiotherapy trials 
(table 4) the level of evidence required to show improved 
outcome might also vary.54 It could be argued that a new 
fractionation schedule or a new combination treatment 
requires assessment in an RCT, whereas the integration 
of a new immobilisation mask might allow a lower level 
of evidence. Other innovations, such as those requiring 
investment in a new technology, might need a 
more blended or model-based approach to evidence 
generation.20,53 Furthermore, high upfront capital 
investments associated with new technologies, typically 
made by health-care providers before their clinical 
validation, and the risk that innovations could quickly 
ESMO-MCBS, ASCO-VF, NCCN-B ICHOM
Evaluation Recommendation
Ranking Benchmarking, quality 
improvement
Measuring magnitude of benefit Definition of outcome measures
Focusing on treatments Addressing the entire disease 
history
Composite value scale Indicators of quality
No current patient involvement Patient-centric, shared 
decision making
By clinicians representing 
organisations
By independent clinicians and 
patients
Level of evidence essential Various evidence allowed
Retrospective Prospective
Oncology Diseases beyond oncology
ESMO-MCBS=European Society for Medical Oncology Magnitude of Clinical 
Benefit Scale. ASCO-VF=American Society of Clinical Oncology Value Framework. 
NCCN-B=National Comprehensive Cancer Network Blocks. ICHOM=International 
Consortium for Health Outcomes Measurement.
Table 7: Comparison between value frameworks and ICHOM
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become outdated because of rapid and incremental 
developments in software and hardware explain why 
RCTs can be difficult to accomplish for radiotherapy 
technologies.20,55
Similarly, surgical innovations could entail the 
development of more advanced surgical techniques that 
allow more complete tumour resections (eg, total 
mesenteric excision) or decrease morbidity while 
obtaining the same level of local control (eg, sleve 
lobectomies obviating the need for pneumonectomy). 
Crucially, this evolution could be related to the 
introduction of new technologies, of which some could 
become popular well before being formally tested in a 
trial. An archetypal example is laparoscopic surgery, 
which was introduced in the mid-1980s and widely 
disseminated before any quality control occurred, yet its 
introduction resulted in shorter hospital stay, improved 
quality of life and better access to surgical treatment in 
some clinical settings. Unfortunately, such evidence of 
superior outcomes are not de facto seen for all new 
surgical technologies (eg, robotic surgery) and not across 
all indications.56 In other situations the technique on its 
own might not be objectively better, but could be taught 
and disseminated more optimally by instructing young 
surgeons on a lab or virtual model, and therefore provide 
improved outcomes as a consequence of better training. 
The use of RCTs in surgical oncology might be 
compromised because of issues related to investment in 
equipment, training of the dedicated personnel, and to 
surgical techniques evolving progressively while skills 
are being enhanced and new tools brought to use. 
Furthermore, it has been observed that one out of five 
surgical oncology trials are abandoned because it is 
usually highly complex to set-up multicentre trials in 
surgery and little funding and operational support are 
available to run the trials.57
Finally, the value of locoregional interventions and 
outcomes obtained crucially depend not only on the 
operators (physician and nurses) but also on the quality 
of the equipment and on a broad range of other 
professionals involved (eg, physicists and dosimetrists in 
the case of radiotherapy and anaesthesia and post-
operative care in surgery).36 Therefore, any benchmarking 
of the expected value or benefit (measured in terms of 
patient outcome) of a new surgical or radiotherapeutic 
intervention must take into account the quality of its 
delivery.57–59
Although these aspects challenge the design and 
execution of trials for locoregional oncology treatments, it 
remains important that high-cost innovations undergo 
robust evaluation as the evidence deficit can adversely 
affect reimbursement decisions, delay clinical adoption of 
innovations, and potentially facilitate widespread adoption 
of interventions that offer no benefit or can result in 
harm.60 Guidance regarding the research methods and 
studies needed to provide adequate evidence on benefit or 
added benefit is a prerequisite for a framework that 
assesses the clinically meaningful benefit of new 
locoregional interventions.61 The IDEAL (idea development, 
exploration, assessment, and long-term follow-up) 
framework was developed to provide a basis for such 
guidance in the field of surgery.54 It emphasises the need to 
ensure the validity and quality of studies during the earlier 
stages of technical development and before RCTs. This 
step would facilitate refinement of the procedure, 
community education, and consideration of alternative 
indications as part of the early development phase. Moving 
away from single-centre, retrospective series as a basis for 
evidence generation and before considering an RCT, the 
authors of the IDEAL recommendations suggest a 
stepwise collaborative collection of non-randomised 
prospective data that focuses on feasibility outcomes, 
adverse event analysis, patient-reported outcome 
measures, and clinical outcomes. RCTs are expected to 
account for surgical learning curves, blinding or masking 
of outcome assessors, assessment of the quality of surgery 
undertaken, and reporting of main outcomes according to 
guidelines such as CONSORT. The IDEAL framework is 
being used by research funders to support prospective 
multicentre exploration studies to inform future RCTs and 
by HTA communities for the assessment of medical 
technologies and devices.62,63 Based on this surgical 
experience, IDEAL has been adapted to radiation oncology 
(R-IDEAL) to provide guidance for evidence generation for 
radiotherapy innovations. It is implemented for the clinical 
evaluation of MRI-guided radiotherapy.64 Fundamental in 
this proposal is the fact that radiotherapy effects can be 
modelled, allowing the prediction of potential treatment 
benefits, and hence facilitate patient selection for specific 
techniques or technologies. Early predicate and modelling 
studies are therefore included in the proposal, whereas the 
ambition to include randomisation at an early stage of 
technology development and the need for long-term 
follow-up for late effects were underlined.
Such frameworks could support the definition of 
different scoring weights in a clinical benefit scale, 
depending on the appropriateness of the evidence 
underpinning the observed benefit.
Value: the balance between outcome and costs
In the context of increasing health-care expenses and 
budgetary restrictions, health economic evidence has 
become a prerequisite before granting reimbursement 
for new health-care interventions. Economic evaluations 
analyse the additional costs incurred and the incremental 
outcomes gained by delivering a new intervention 
compared with existing alternatives of care. The resulting 
ratio, the incremental cost-effectiveness ratio provides 
the balance between costs and outcomes—during 
treatment and in the years thereafter—and is used to 
inform stakeholders that plan, provide, or pay for the 
health services under evaluation.65
In oncology, this type of analysis, part of a broader HTA 
programme, is almost standard for new anticancer 
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drugs. Yet, such rigour is not typically applied to the 
adoption of technologies. Reasons underlying this lack of 
transference are a combination of scarce availability of 
comparative effectiveness data and the incremental 
nature of technology evolution, resulting in difficulties in 
accurately capturing real costs and long-term clinical 
outcome.20,55 Additionally, health economic evaluations 
are often erroneously perceived as a means to cut costs or 
to block or slow down access to innovative treatment 
strategies that are often more expensive. At a European 
level, discussions are ongoing to harmonise HTA 
programmes of drugs and technologies; however, no 
consensus has been reached as yet.27,28
In essence, Porter’s definition of value also addresses 
this balance between costs and outcomes, yet the central 
focus is shifted towards increasing value through 
improved outcome for patients (ie, optimising health 
outcomes achieved per dollar spent).8 Although the 
available value frameworks all provide a method to define 
clinical benefit, their approach regarding the costs differs 
(table 2). ESMO-MCBS does not consider costs,9,10 
ASCO-VF includes the costs of the medicine to the health-
care system and the patient without consideration of other 
costs,11,12 and NCCN-B includes economic considerations 
by defining affordability in a broad sense.13
In the examples of ASCO-VF and NCCN-B, the costs 
are determined by their reimbursement tariffs.11–13 
Although they could represent the cost from a health-
care perspective, they have typically been defined through 
negotiations and hence are not necessarily a good proxy 
for the real costs of the intervention.66 According to 
Kaplan and Porter67 one of the major problems of current 
health-care systems is the scarcity of good cost data 
obtained with validated cost-accounting methods. 
Accurate resource cost data are indeed scarce in 
radiotherapy and the use of validated cost-accounting 
models is infrequent.22,66 The same scarcity is observed in 
surgery. Yet, in view of allocating the adequate payment 
to each individual intervention, accounting for its degree 
of technical and clinical complexity, the importance of 
understanding the cost of new and established health-
care interventions cannot be overstated.68 To address this 
need in radiotherapy, ESTRO’s Health Economics in 
Radiation Oncology project has developed a time-driven 
activity-based costing model to calculate the cost of 
external-beam radiotherapy at a national level.69,70
Towards an evidence-informed value 
framework for surgical and radiation oncology
Two main considerations emerge from this analysis with 
respect to developing a value framework for surgical and 
radiation oncology treatments. First, for each specific 
intervention it is important to capture the relevant 
endpoints that matter most to patients, in the context of a 
particular oncological setting and indication. Second, 
one must consider how evidence is generated given the 
heterogeneity across radiotherapy and surgical treatment 
strategies. Both aspects should form the cornerstone of a 
clinically meaningful benefit scale—or scales—that 
appraise new interventions in locoregional cancer 
treatment. In the development of such a framework, 
two core steps and a series of evaluations should be 
undertaken.
Step one: defining core sets of endpoints for 
locoregional cancer treatments by multi-stakeholder 
collaboration
Recent projects have shown the feasibility of involving 
multiple stakeholders to develop a set of core outcome 
measures primarily reflecting the needs of patients 
undergoing surgery for specific cancers.51,52 Conversely, 
ICHOM has defined outcome sets for specific cancer types 
across therapeutic interventions.14,41–45 Building further on 
such experiences, the harmonisation of outcome sets for 
surgical and radiation oncology interventions would 
facilitate the development of clinically meaningful benefit 
scales that prioritise endpoints defined through multi-
stakeholder engagement.
Although the challenge will be in finding the acceptable 
balance between harmonisation and specificity towards 
Figure: Core aspects to consider in the development of an evidence-informed value scale for surgical and 
radiation oncology
Four different aspects should be accounted for in the development of a value scale for surgical and radiation 
oncology: (1) distinguish between innovations that evolve stepwise and those that evolve incrementally; 
(2) develop a grading system including various levels of evidence and considering the respective types of 
innovation; (3) differentiate between curative and non-curative intent; (4) define, through multi-stakeholder 
collaboration, a core set of endpoints, including survival, toxicity, complications and functional outcomes, quality 
of life and patient-reported outcomes, and economic and operational endpoints. RCT=randomised controlled trial. 
QoL=quality of life. PROMS=patient-reported outcome measures.
Type of intervention
Stepwise innovations in locoregional cancer 
treatments:
•  New dose fractionation schedules
•  the addition of biological or chemotherapeutic 
 drugs
•  Interventions or technologies requiring 
 re-training)
Incremental innovations in locoregional cancer
treatments:
•  New immobilisation devices
•  New technologies for target localisation
•  New surgical instruments) 
Level of evidence
•  RCTs
•  Non-inferiority trials
•  Model-based studies
•  Prospective non-randomised studies
•  Pragmatic observational cohort studies
•  Real-world evidence
Core set of endpoints
Intent of the intervention 
Curative Non-curative
Economic
endpoints
Survival
Toxicity
QoL,
PROMS
•  Non-inferiority trials
•  Model-based studies
•  Prospective non-randomised studies
•  Pragmatic observational cohort studies
•  Real-world evidence
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the type of cancer and the type of intervention, such 
commonly agreed-upon core sets of endpoints should 
enable comparative evaluation of a large body of different 
intervention studies.
Step two: creating a clinically meaningful benefit scale 
for surgical and radiation oncology treatments
Creating such a scale will require substantial conceptual 
development and testing because of the complexities 
outlined in this Review. The figure shows the core aspects 
that in our view would need to be considered beyond those 
used in ESMO-MCBS and ASCO-VF. First separation of 
the types of interventions into two broad groups should be 
considered: new interventions that can be regarded as 
innovations potentially improving outcome in a stepwise 
fashion (eg, new dose fractionation schedules in 
radiotherapy, the addition of systemic drugs to standard 
radiotherapy or surgery practice, and inter ventions or 
technologies requiring retraining) versus those that 
represent incremental technological innovations (eg, new 
immobilisation devices, new techniques for target 
localisation, and new surgical instruments). This 
separation is proposed as it is likely that the evidence 
requirement before clinical integration for these two 
groups should be different, with stepwise innovations 
necessitating more robust prospective or randomised 
evaluation because of the effect on long-term survival, 
toxicity, and quality of life. Table 4 includes many such 
studies. The other type of innovations reflect the 
incremental upgrades that are continuously being 
undertaken to radiotherapy hardware and software with 
the aim of achieving greater efficiency, safety, and 
improving usability; or the continuum of evolving surgical 
instruments and techniques that are designed to facilitate 
the intervention and ameliorate outcomes. Although 
conceptually logical and pragmatic, such a clear distinction 
between stepwise and incremental innovations might not 
always be evident. Second, different levels of evidence 
beyond the formal RCT should be considered, such as 
non-inferiority trials, model-based studies, prospective 
non-randomised or pragmatic observational cohort 
studies, as well as real-world evidence.61,71,72 A grading 
system will have to be developed that will reflect the 
hierarchy of this evidence in view of the type of intervention 
and the various endpoints considered. Third, similar to the 
approach in ESMO-MCBS, it remains important to 
consider the intent of the intervention (curative versus 
non-curative), especially for stepwise innovations because 
this consideration will influence both the endpoints 
defined and the magnitude of improvement that should be 
achieved to be meaningful. As the typical boundaries 
between localised (curative) and disseminated (non-
curative) disease are currently fading (eg, in oligometastatic 
disease) this distinction is not trivial. Lastly, it is our view 
that endpoints in the core sets of endpoints, defined 
through multi-stakeholder collaboration, should be 
categorised into groups that consider: (1) survival including 
overall survival, but potentially encompassing a broader 
range of survival endpoints as shown in the evaluated 
trials; (2) toxicity, complications, and functional outcomes, 
where a clear distinction between the relative effect of 
acute and late (chronic) effects should be given attention; 
(3) quality of life and patient-reported outcomes using 
validated scales; and (4) economic and operational 
endpoints including resource use, costs, and quality.
Within and across these categories, endpoints will have 
to be weighted and scaled by considering the value they 
represent for the patients affected by different cancer 
types. In our view the inclusion of economic endpoints 
into the core endpoints is important in order to define 
more explicitly the value of new health-care interventions, 
especially in the context of non-inferiority studies.
Conclusion
The multi-stakeholder international oncology community 
needs to provide direction on the outcomes most valued 
by patients, the levels of evidence that are acceptable 
when considering the merits of new technologies in 
patient populations, and what evidence is required before 
rapid clinical adoption. The existence of an initial 
benchmarking of the value of new drugs by regulatory 
agencies who grant or do not grant market authorisation 
has greatly facilitated the development of value scales for 
systemic anticancer treatments. A similar assessment 
should be developed for locoregional cancer therapies, 
Search strategy and selection criteria
This Review was prepared by a taskforce mandated by the 
Board and the Oncopolicy Committee of the European CanCer 
Organisation (ECCO), which comprises medical, policy, and 
patient advocacy experts. Besides ECCO and its Patient 
Advisory Committee, the authors represent the European 
Society for Radiotherapy and Oncology, the European Society 
of Surgical Oncology, and the European Organisation for 
Research and Treatment of Cancer. Value frameworks were 
evaluated and selected following expert consensus, supported 
by the fact that they are developed by large professional bodies, 
are broadly studied in the literature on value in oncology, and 
allow methodological appraisal. The references included were 
identified by the experts and no systematic literature review 
was performed. An extraction table was defined upfront, on the 
basis of which three collaborators (AA, CG, and YL) extracted 
the data from the articles. These were subsequently discussed 
and agreed upon in a live meeting where all co-authors (except 
KO) participated. The results were subsequently summarised in 
tables 1–3 as presented. The surgical and radiation oncology 
clinical trials that were evaluated with these frameworks were 
indentified by two experts (AA and YL), on the basis of their 
practice-changing potential (eg, if the results of the trials were 
integrated in practice guidelines) and reflecting a variable range 
of indications, cancer types, and interventions. The appraisal 
was performed by the same two authors.
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such as surgery and radiotherapy. Such a mechanism, 
ideally in the form of a practical tool or scale, should 
include evidence from real-world (ie, data from patients 
treated in daily practice) and clinical trials and include the 
whole spectrum of patient-centred endpoints. This type 
of scale could help optimise patient access to high-value 
developments in surgery and radiotherapy, ultimately 
raise the evidence bar for new innovations introduced 
into clinical practice, and ensure that investment in 
research and development provides the opportunity for 
substantial improvement in cancer care.
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